PLX Earnings Date & History
Protalix Biotherapeutics Inc (NYSE MKT LLC) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:36 PM ET
Protalix Biotherapeutics Inc
Biotechnology
- Next earnings date
- Wednesday, November 11, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.02
- Revenue estimate
- $15.0M
PLX earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, August 12, 2026 | Q2 2026 | $-0.01 | $0.05 | +595.0% | $19.9M |
| Wednesday, May 13, 2026 | Q1 2026 | $-0.01 | $0.22 | +2278.2% | $33.8M |
| Wednesday, February 11, 2026 | Q4 2025 | $0.01 | $-0.07 | -1472.5% | $9.1M |
| Thursday, November 13, 2025 | Q3 2025 | $0.06 | $0.03 | -46.0% | $17.9M |
| Thursday, August 14, 2025 | Q2 2025 | $0.03 | $0.00 | -100.0% | $15.7M |
What the market is watching in PLX's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next PLX earnings date?
- Protalix Biotherapeutics Inc is scheduled to report on Wednesday, November 11, 2026 (Time TBD). Dates can change until the company confirms them.
- Does PLX report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for PLX?
- Consensus EPS for the upcoming quarter is $-0.02, on revenue of $15.0M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
PLX earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.